ABIOMED Valuation
Based on Macroaxis valuation methodology, the entity cannot be evaluated at this time. ABIOMED prevailing Real Value cannot be determined due to lack of data. The current price of ABIOMED is $0.0. Our model approximates the value of ABIOMED from evaluating the entity fundamentals such as Current Valuation of 16.32 B, shares outstanding of 45.09 M, and Profit Margin of 0.25 % as well as inspecting its technical indicators and probability of bankruptcy. In general, most investors favor purchasing undervalued instruments and exiting overvalued instruments since, at some future date, asset prices and their ongoing real values will blend.
Undervalued
Today
Please note that ABIOMED's price fluctuation is out of control at this time. Calculation of the real value of ABIOMED is based on 3 months time horizon. Increasing ABIOMED's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for ABIOMED is useful when determining the fair value of the ABIOMED stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of ABIOMED. Since ABIOMED is currently traded on the exchange, buyers and sellers on that exchange determine the market value of ABIOMED Stock. However, ABIOMED's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0 | Real 0.0 | Hype 0.0 |
The real value of ABIOMED Stock, also known as its intrinsic value, is the underlying worth of ABIOMED Company, which is reflected in its stock price. It is based on ABIOMED's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of ABIOMED's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence ABIOMED's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of ABIOMED helps investors to forecast how ABIOMED stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ABIOMED more accurately as focusing exclusively on ABIOMED's fundamentals will not take into account other important factors: ABIOMED Valuation Ratios as Compared to Competition
Comparative valuation techniques use various fundamental indicators to help in determining ABIOMED's current stock value. Our valuation model uses many indicators to compare ABIOMED value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ABIOMED competition to find correlations between indicators driving ABIOMED's intrinsic value. More Info.ABIOMED is number one stock in price to earning category among related companies. It is number one stock in price to book category among related companies fabricating about 0.15 of Price To Book per Price To Earning. The ratio of Price To Earning to Price To Book for ABIOMED is roughly 6.86 . Comparative valuation analysis is a catch-all model that can be used if you cannot value ABIOMED by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for ABIOMED's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ABIOMED's earnings, one of the primary drivers of an investment's value.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates ABIOMED's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in ABIOMED and how it compares across the competition.
About ABIOMED Valuation
The delisted stock valuation mechanism determines the current worth of ABIOMED on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of ABIOMED. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of ABIOMED based exclusively on its fundamental and basic technical indicators. By analyzing ABIOMED's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of ABIOMED's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of ABIOMED. We calculate exposure to ABIOMED's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to ABIOMED's related companies.Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. Abiomed operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 2003 people.
8 Steps to conduct ABIOMED's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates ABIOMED's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct ABIOMED's valuation analysis, follow these 8 steps:- Gather financial information: Obtain ABIOMED's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine ABIOMED's revenue streams: Identify ABIOMED's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research ABIOMED's industry and market trends, including the size of the market, growth rate, and competition.
- Establish ABIOMED's growth potential: Evaluate ABIOMED's management, business model, and growth potential.
- Determine ABIOMED's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate ABIOMED's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
ABIOMED Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as ABIOMED does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 45.9 M | |
| Quarterly Earnings Growth Y O Y | 0.871 | |
| Retained Earnings | 964.5 M | |
| Retained Earnings Total Equity | 964.5 M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Consideration for investing in ABIOMED Stock
If you are still planning to invest in ABIOMED check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ABIOMED's history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |